Your browser doesn't support javascript.
loading
[Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure]. / Respuesta hematológica y molecular en leucemia mieloide crónica (LMC) con falla a tratamiento con dasatinib como fármaco de segunda línea.
Santos-Macías, Juan Enrique; Baez de la Fuente, Enrique; Salas-Delgado, Arnoldo.
Afiliação
  • Santos-Macías JE; Departamento de Hematología, UMAE No 25, Monterrey, N.L., México.
  • Baez de la Fuente E; Departamento de Hematología, UMAE No 25, Monterrey, N.L., México.
  • Salas-Delgado A; Departamento de Hematología, UMAE No 25, Monterrey, N.L., México.
Gac Med Mex ; 152(3): 334-8, 2016.
Article em Es | MEDLINE | ID: mdl-27335188
BACKGROUND: Chronic myeloid leukemia is a myeloproliferative disease characterized by the Philadelphia chromosome and with this, the chimeric protein BCR-ABL. The first-line treatment is imatinib, a tyrosine kinase inhibitor, that has showed good results, but with a significant percentage of treatment failure. This failure has led to second-generation tyrosine kinase inhibitors as second-line treatment such as dasatinib. OBJECTIVES: The objective of the study was to evaluate the efficacy of dasatinib as second-line treatment. MATERIAL AND METHODS: Observational, longitudinal, and retrospective study. Patients with diagnosis of chronic myeloid leukemia that presented failure to first-line treatment were included in the present study; the hematologic response was evaluated at 3, 6, and 12 months, and molecular response at 12 months of follow-up after dasatinib treatment was started. RESULTS: Of a total of 14 patients that were included in the study, a response in the white cell count of 84.6% with a mean response at 4.7 months of follow-up was observed; also 84.6% platelet response with a mean response at 4.7 months of follow-up. Molecular response was also evaluated at a 12-month follow-up, achieving a 50% response with a mean response at 11.08 months of follow-up. A survival rate of 80% at a 12-month follow-up was observed. CONCLUSIONS: The use of dasatinib as a second-line treatment is effective in achieving a sustained hematologic response of 84.6% and a molecular response in 50%, also finding a hematologic response without achieving a total molecular response.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases / Dasatinibe Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Humans / Male / Middle aged Idioma: Es Revista: Gac Med Mex Ano de publicação: 2016 Tipo de documento: Article País de publicação: México
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases / Dasatinibe Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Humans / Male / Middle aged Idioma: Es Revista: Gac Med Mex Ano de publicação: 2016 Tipo de documento: Article País de publicação: México